Hain Celestial (HAIN) Misses Q3 EPS by 10c
Tweet
Share
E-mail
Get Alerts HAIN Hot Sheet
Revenue Growth %: -26.9%
Financial Fact:
Provision for income taxes: 21.58M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Hain Celestial (NASDAQ: HAIN) reported Q3 EPS of $0.37, $0.10 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $632.7 million versus the consensus estimate of $747.24 million.
The Company's previously issued guidance was inclusive of Hain Pure Protein's results, and therefore, the Company has updated its guidance to exclude Hain Pure Protein. Additionally, the Company updated Adjusted EPS and Adjusted EBITDA guidance for fiscal year 2018 to reflect the results of current operations, continued higher investment in marketing and brand awareness, primarily in the United States, as well as increased freight and certain commodity price headwinds:
Original Guidance | Less:Hain Pure Protein | Adjusted Guidance | Updated FY 2018 Guidance | ||||||||
Low | High | Low | High | Low | High | ||||||
Net Sales ($M) | $ 2,967 | $ 3,036 | $ (533) | $ 2,434 | $ 2,503 | $ 2,434 | $ 2,503 | ||||
Adjusted EBITDA ($M) | $ 340 | $ 355 | $ (48) | $ 292 | $ 307 | $ 250 | $ 260 | ||||
Adjusted EPS(1) | $ 1.64 | $ 1.75 | $ (0.25) | $ 1.39 | $ 1.50 | $ 1.11 | $ 1.18 | ||||
For earnings history and earnings-related data on Hain Celestial (HAIN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
- MP Materials seen largely insulated after China export-control move
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
